Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EPL LIMITED M&A Activity 2026

Mar 29, 2026

60801_rns_2026-03-29_81043a1b-ce35-4b7d-a198-c7a0db3da683.pdf

M&A Activity

Open in viewer

Opens in your device viewer

==> picture [596 x 99] intentionally omitted <==

March 29, 2026

BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C/1, Block G, Dalal Street, Mumbai - 400001 Bandra-Kurla Complex, Bandra (E), Mumbai - 400051 Scrip Code: 500135 Trading Symbol: EPL

Sub. : Outcome of the Board Meeting - EPL Limited (“Company”)

  • Ref. : 1. Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (“SEBI LODR Regulations”)

  • 2. ISIN: INE255A01020

Sir/ Madam,

Pursuant to the provisions of Regulation 30 of the SEBI LODR Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (“ SEBI Circular ”) it is hereby informed that the Board of Directors of the Company (“ Board ”) has, at its meeting held today i.e. March 29, 2026, inter alia , considered and approved the following:

  1. Scheme of amalgamation (by way of merger by absorption) of Indovida India Private Limited (“ Indovida India ”) with the Company and their respective shareholders (“ Scheme ”), on a going concern basis, under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and the rules framed thereunder read with the SEBI LODR Regulations and the relevant circulars issued by the Securities and Exchange Board of India, in consideration for the issuance and allotment of the equity shares of the Company to the shareholders of Indovida India in accordance with the share exchange ratio stipulated in the Scheme (“ Merger ”).

The Merger is subject to necessary statutory and regulatory approvals under the applicable laws, including approval of/ from: (a) the BSE Limited and the National Stock Exchange of India Limited (collectively, “ Stock Exchanges ”); (b) the Securities and Exchange Board of India (“ SEBI ”), (c) the requisite majority of the shareholders and creditors of the Company and Indovida India; (d) the jurisdictional National Company Law Tribunal (“ NCLT ”); (e) the Competition Commission of India (“ CCI ”); and (f) other statutory and regulatory approvals as may be required.

  1. Execution of the Merger Implementation Agreement by and amongst the Company, Indovida India and Indorama Netherlands B.V. (“ IVL ”) (“ MIA ”);

  2. Execution of the Shareholders’ Agreement by and amongst the Company, Epsilon Bidco Pte. Ltd., and IVL (“ SHA ”); and

  3. Execution of the Transition Services Agreement by and amongst the Company, IVL and Indorama Ventures Global Services Limited (“ TSA ”).

==> picture [596 x 77] intentionally omitted <==

Page 1 of 14

==> picture [596 x 99] intentionally omitted <==

In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI LODR Regulations read with Para A of Part A of Schedule III of the SEBI LODR Regulations and the SEBI Circular:

  1. For the Merger are enclosed herewith as Annexure A

  2. For the MIA are enclosed herewith as Annexure B ;

  3. For the SHA are enclosed herewith as Annexure C ; and

  4. For the TSA are enclosed herewith as Annexure D .

The copy of press release being submitted to media is also enclosed herewith.

The meeting of the Board commenced at 5:00 P.M. (IST) and concluded at 5:25 P.M. (IST)

We request you to kindly take the same on record.

Thanking you,

Yours faithfully, For EPL Limited ONKAR DEEPAK Digitally signed by ONKAR DEEPAK GHANGURDE GHANGURDE Date: 2026.03.29 17:48:45 +05'30' Onkar Ghangurde Head - Legal, Company Secretary & Compliance Officer ICSI Membership No. A30636

Encl.: As above

==> picture [596 x 77] intentionally omitted <==

Page 2 of 14

==> picture [596 x 99] intentionally omitted <==

Annexure A

Sr.
No.
Particulars Description
1. Name of the entity(ies) forming part of the
amalgamation/merger, details in brief
such as, size, turnover etc.
1.
2.
3.
Transferee
Company:
EPL
Limited
(“Company”)
Transferor Company: Indovida India Private
Limited (“Indovida India”)
Details of turnover and net-worth as on
December 31, 2025 on a consolidated basis:
(in INR Crores)
Particulars
Company
(Jan-Dec’25)
Indovida
India
(Jan-Dec’25)
Turnover
4,568
3,809
Net-worth
1,717
6,459
Note:
_
The details of Indovida India include the effect of_
consummation of the acquisition of Indovida
Netherlands B.V. (and its subsidiaries) by Indovida
India from Indorama Netherlands B.V.
2. Whether the transaction would fall within
related party transactions? If yes, whether
the same is done at “arm’s length”
Indorama Netherlands B.V. (“IVL”) holds
24.44% stake in the Company (on a fully diluted
basis) as on March 29, 2026, and also holds
99.99% of the share capital of Indovida India.
In terms of General Circular No. 30/2014 dated
July 17, 2014, issued by Ministry of Corporate
Affairs, the transactions arising out of
compromises,
arrangements
and
amalgamations under the Companies Act,
2013, will not attract the requirements of
Section 188 of the Companies Act, 2013.
The share exchange ratio has been determined
based on joint valuation report issued by the
independent valuers, supported by a fairness
opinion obtained from a SEBI registered
merchant banker. The Merger is therefore at
arm’s length basis.

==> picture [596 x 77] intentionally omitted <==

Page 3 of 14

==> picture [596 x 99] intentionally omitted <==

Sr.
No.
Particulars Description
3. Area of business of the entity(ies) The Company, along with its subsidiaries and
associate, is engaged in the business of,inter
alia, of manufacturing and selling of packaging
products including extruded and laminated
plastic tubes, laminates, caps and closures
globally for products in the beauty and
cosmetics, health and pharmaceuticals, food,
home and oral care categories.
Indovida India, along with its subsidiary and
associate companies, is engaged in the business
of_, inter alia_, manufacturing of packaging
products and trading of raw materials used in
manufacture of packaging products.
4. Rationale for amalgamation/ merger The amalgamation of Indovida India with the
Company will result in the following benefits:
(a) the Company shall be better positioned to
deliver wider range of products and
services
to
customers
through
the
combined operations of the Company and
Indovida India;
(b) geographical
diversification
and
enhancement
of
operational,
organizational and financial efficiencies,
thereby
achieving
cost
savings
and
synergies through the pooling of resources;
(c) an integrated approach will facilitate
enhanced efficiency in consolidation of
financials, allocation of capital and cash
management;
(d) implementation of best practices and the
strategic
advancement
of
process
automation by leveraging cutting-edge
technologies; and
(e) improved organizational capability and
leadership, arising from the effective
pooling of human capital which brings
together diverse skills, exceptional talent,
and vast experience essential for driving
operational
excellence
and
delivering
sustained value to stakeholders.

==> picture [596 x 77] intentionally omitted <==

Page 4 of 14

==> picture [596 x 99] intentionally omitted <==

Sr.
No.
Particulars Description Description Description
5. In case of cash consideration – amount or
otherwise share exchange ratio
Upon the Merger becoming effective, the
Company shall issue and allot to each
shareholder of Indovida India 286 fully paid-up
equity shares of face value INR 2 each of the
Company, for every 10,000 fully paid-up equity
shares of face value INR 10 each held by such
shareholder in Indovida India.
The share exchange ratio for the Merger is
based on the joint valuation report dated
March 28, 2026, issued by BDO Valuation
Advisory LLP and D and P India Advisory
Services, Independent Registered Valuers.
Ernst & Young Merchant Banking Services LLP,
a SEBI registered Category-I Merchant Banker
has provided the fairness opinion vide its report
dated March 28, 2026 on the fairness of the
aforesaid share exchange ratio.
6. Brief details of change in shareholding
pattern (if any) of listed entity
Company:
Pre-amalgamation shareholding

fully diluted basis*:
Category No. of Shares %
Promoter /
Promoter Group
8,44,79,781 25.97
Public 24,08,29,927 74.03
Total 32,53,09,708 100.00

fully diluted basis:
Category No. of Shares %
Promoter /
Promoter Group
34,87,01,552 68.37
Public 16,13,35,842 31.63
Total 51,00,37,394 100.00

Note : Capitalised terms used and not defined herein, if any, shall have the meanings ascribed to them in the main intimation.

==> picture [596 x 77] intentionally omitted <==

Page 5 of 14

Annexure B

==> picture [596 x 99] intentionally omitted <==

Sr.
No.
Particulars Description
1. If the listed entity is a party to the
agreement,
i.
details of the counterparties (including
name and relationship with the listed
entity)
The following entities are party to the merger
implementation agreement (“MIA”):
(a) EPL Limited (“Company”);
(b) Indovida India Private Limited (“Indovida
India”); and
(c) Indorama Netherlands B.V. (“IVL”).
2. If listed entity is not a party to the
agreement,
i. name of the party entering into such
an agreement and the relationship
with the listed entity;
ii. details of the counterparties to the
agreement
(including
name
and
relationship with the listed entity);
iii. date of entering into the agreement
Not Applicable
3. Purpose of entering into the agreement The MIA sets out the manner of effecting the
transactions envisaged in the Scheme and the
rights and obligations of the parties in relation
thereto.
4. Shareholding, if any, in the entity with
whom the agreement is executed
IVL holds 24.44% shareholding in the Company
on a fully diluted basis as on March 29, 2026,
and also holds 99.99% of the share capital of
Indovida India.
Indovida India does not hold any shareholding
in the Company.
Further, the Company does not hold any
shareholding in Indovida India or IVL.
5. Significant terms of the agreement (in
brief)
The MIA sets out the manner of effecting the
transactions envisaged in the Scheme and the
rights and obligations of the parties in relation
thereto. Certain significant terms of the MIA
have been summarised below:

==> picture [596 x 77] intentionally omitted <==

Page 6 of 14

==> picture [596 x 99] intentionally omitted <==

Sr.
No.
Particulars Description Description
(a) key conditions for the implementation of
the Scheme, which_inter alia_, includes:
(i) receipt of necessary approvals, such as
approval of the Scheme by the NCLT, CCI,
the Stock Exchanges under Regulation 37 of
the SEBI LODR Regulations, approval by the
respective requisite majorities of each class
of shareholders and creditors of Indovida
India and the Company; and (ii) completion
of acquisition of the entire stake of Indovida
Netherlands B.V. (and its subsidiaries) by
Indovida India from IVL;
(b) customary standstill obligations on Indovida
India and the Company; and
(c) sequence of events to be undertaken for
the Scheme to be effective.
6. Extent and the nature of impact on
management or control of the listed entity
Please refer point 6 in Annexure C below.
7. Details and quantification of the restriction
or liability imposed upon the listed entity
There are customary covenants with respect to
standstill obligations until the earlier of: (a) the
Scheme coming into effect; and (b) the date on
which the MIA is terminated.
8. Whether, the said parties are related to
promoter/
promoter
group/
group
companies in any manner. If yes, nature of
relationship
No
9. Whether the transaction would fall within
related party transactions? If yes, whether
the same is done at “arm’s length”
Please refer point 2 in Annexure A above.
10. In case of issuance of shares to the parties,
details of issue price, class of shares issued

Upon the Merger becoming effective, the
Company shall issue and allot to each
shareholder of Indovida India 286 fully paid-up
equity shares of face value INR 2 each of the
Company, for every 10,000 fully paid-up equity
shares of face value INR 10 each held by such
shareholder in Indovida India.

==> picture [596 x 77] intentionally omitted <==

Page 7 of 14

==> picture [596 x 99] intentionally omitted <==

Sr.
No.
Particulars Description
The share exchange ratio for the Merger is
based on the joint valuation report dated
March 28, 2026, issued by BDO Valuation
Advisory LLP and D and P India Advisory
Services, Independent Registered Valuers.
Ernst & Young Merchant Banking Services LLP,
a SEBI registered Category-I Merchant Banker
has provided the fairness opinion vide its report
dated March 28, 2026 on the fairness of the
aforesaid share exchange ratio.
11. Any other disclosures related to such
agreements, viz., details of nominee on the
board of directors of the listed entity,
potential conflict of interest arising out of
such agreements, etc.
Not applicable.
12. In case of rescission, amendment or
alteration, listed entity shall disclose
additional details to the stock exchange(s):
i. name of parties to the agreement;
ii. nature of the agreement;
iii. date of execution of the agreement;
iv. details and reasons for amendment or
alteration
and
impact
thereof
(including impact on management or
control and on the restriction or
liability quantified earlier);
v. reasons for rescission and impact
thereof
(including
impact
on
management or control and on the
restriction
or
liability
quantified
earlier).

Not applicable.

Note : Capitalised terms used and not defined herein, if any, shall have the meanings ascribed to them in the main intimation.

==> picture [596 x 77] intentionally omitted <==

Page 8 of 14

Annexure C

==> picture [596 x 99] intentionally omitted <==

Sr.
No.
Particulars Description
1. If the listed entity is a party to the
agreement,
i. details of the counterparties (including
name and relationship with the listed
entity)
The following entities are party to the
shareholders’ agreement (“SHA”):
(a) EPL Limited (“Company”);
(b) Epsilon Bidco Pte. Ltd. (“Epsilon”); and
(c) Indorama Netherlands B.V. (“IVL”).
2. If listed entity is not a party to the
agreement,
i. name of the party entering into such
an agreement and the relationship
with the listed entity;
ii. details of the counterparties to the
agreement
(including
name
and
relationship with the listed entity);
iii. date of entering into the agreement
Not Applicable
3. Purpose of entering into the agreement The purpose of entering into the SHA is to
define the mutual rights and obligations of the
parties, and to set out the terms governing the
relationship between Epsilon and IVL, and their
relationship with the Company, following the
consummation of the Merger.
4. Shareholding, if any, in the entity with
whom the agreement is executed
The Company has no shareholding in any of the
parties to the SHA.
Epsilon holds 25.97% shareholding in the
Company on a fully diluted basis, as on March
29, 2026.
IVL holds 24.44% shareholding in the Company
on a fully diluted basis, as on March 29, 2026.
5. Significant terms of the agreement (in
brief)
The SHA provides for the following significant
terms:
(a) Epsilon has the right to nominate 1 (one)
director and IVL has the right to nominate at
least 3 (three) directors on the Board of the
Company.

==> picture [596 x 77] intentionally omitted <==

Page 9 of 14

==> picture [596 x 99] intentionally omitted <==

Sr.
No.
Particulars Description
(b) Prior approval of both Epsilon and IVL is
required to be obtained by the Company in
respect of certain reserved matters.
(c) Epsilon and IVL can freely transfer their
shares, subject to the restrictions set out in
the SHA.
(d) IVL will be subject to certain non-compete
obligations from the effectiveness of the
Merger, and Epsilon will be subject to
certain non-solicit obligations from the
effectiveness of the Merger.
6. Extent and the nature of impact on
management or control of the listed entity
(a) Epsilon has the right to nominate 1 (one)
director and IVL has the right to nominate
at least 3 (three) directors on the Board of
the Company.
(b) Prior written approval of both Epsilon and
IVL is to be obtained by the Company in
respect of certain reserved matters.
7. Details and quantification of the restriction
or liability imposed upon the listed entity
Not applicable
8. Whether, the said parties are related to
promoter/promoter
group/
group
companies in any manner. If yes, nature of
relationship
As on the date of this intimation, Epsilon is a
promoter of the Company.
Upon the Scheme coming into effect, IVL will
also be classified as a promoter of the
Company.
9. Whether the transaction would fall within
related party transactions? If yes, whether
the same is done at “arm’s length”
Not applicable.
10. In case of issuance of shares to the parties,
details of issue price, class of shares issued
Not applicable.
11. Any other disclosures related to such
agreements, viz., details of nominee on the
board of directors of the listed entity,
potential conflict of interest arising out of
such agreements, etc.
Not applicable.

==> picture [596 x 77] intentionally omitted <==

Page 10 of 14

==> picture [596 x 99] intentionally omitted <==

Sr.
No.
Particulars Description
12. In case of rescission, amendment or
alteration, listed entity shall disclose
additional details to the stock exchange(s):
i. name of parties to the agreement;
ii. nature of the agreement;
iii. date of execution of the agreement;
iv. details and reasons for amendment or
alteration
and
impact
thereof
(including impact on management or
control and on the restriction or
liability quantified earlier);
v. reasons for rescission and impact
thereof
(including
impact
on
management or control and on the
restriction
or
liability
quantified
earlier)

Not applicable.

Note : Capitalised terms used and not defined herein, if any, shall have the meanings ascribed to them in the main intimation.

==> picture [596 x 77] intentionally omitted <==

Page 11 of 14

==> picture [596 x 99] intentionally omitted <==

Annexure D

Sr.
No.
Particulars Description
1. Name(s) of parties with whom the
agreement is entered
The following entities are party to the transition
services agreement (“TSA”):
(a) EPL Limited (“Company”);
(b) Indorama Ventures Global Services Limited
(“IVGSL”); and
(c) Indorama Netherlands B.V. (“IVL”).
2. Purpose of entering into the agreement Upon the Scheme coming into effect, IVGSL will
provide or procure the provision of certain
support services to the Company and certain
subsidiaries of the Company until the expiry of
5 (five) or 10 (ten) years, as applicable.
3. Size of agreement The transition services are to be provided to the
Company and certain subsidiaries of the
Company at the same cost charged by IVGSL to
its group companies in connection with the
provision of these services.
The aggregate service fees payable in calendar
year 2026 shall not exceed:
(a) USD 1,030,000, in respect of the Transition
Services set out in Part A of Schedule 1 of
the TSA; and
(b) USD 1,370,000, in respect of the Transition
Services set out in Part B of Schedule 1 of
the TSA.
4. Shareholding, if any, in the entity with
whom the agreement is executed
The Company has no shareholding in any of the
parties to the TSA.
As on the date of this intimation, IVL holds
24.44% shareholding in the Company on a fully
diluted basis, as on March 29, 2026.
5. Significant terms of the agreement (in
brief) special rights like right to appoint
directors, first right to share subscription
in case of issuance of shares, right to
restrict any change in capital structure etc.
The significant terms of the TSA are as below:
(a) The term for services under Part A of
Schedule 1 of the TSA is 5 years from the
effectiveness of the Merger, and for the
service under Part B of Schedule 1 of the
TSA is 10 years from the effectiveness of the
Merger.

==> picture [596 x 77] intentionally omitted <==

Page 12 of 14

==> picture [596 x 99] intentionally omitted <==

Sr.
No.
Particulars Description
(b) IVL, at the option of the Company, will
supply certain raw materials to the
Company and its subsidiaries for period of 7
years post the effectiveness of the Merger
(and to its group entities pre-merger) on the
same commercial terms applicable in the
calendar year 2025.
(c) No special rights such as appointment of
directors, first right to share subscription or
right to restrict any change in capital
structure are granted under the TSA.
6. Whether, the said parties are related to
promoter/promoter
group/
group
companies in any manner. If yes, nature of
relationship
Upon the Scheme coming into effect, IVL will
also be classified as a promoter of the
Company.
7. Whether the transaction would fall within
related party transactions? If yes, whether
the same is done at “arm’s length”
The transaction would fall within related party
transactions, as post the Merger, IVGSL, IVL and
the Company will form part of the same group.
The TSA has been negotiated on an arm’s
length basis, with services to be provided at the
same cost that was charged by IVGSL.
8. In case of issuance of shares to the parties,
details of issue price, class of shares issued
Not applicable.
9. In case of loan agreements, details of
lender/borrower, nature of the loan, total
amount of loan granted/taken, total
amount outstanding, date of execution of
the
loan
agreement/sanction
letter,
details of the security provided to the
lenders / by the borrowers for such loan or
in case outstanding loans lent to a party or
borrowed from a party become material
on a cumulative basis
Not applicable.
10. Any other disclosures related to such
agreements, viz., details of nominee on the
board of directors of the listed entity,
Please refer to the disclosure in Sr. No. 5 of this
Annexure D.

==> picture [596 x 77] intentionally omitted <==

Page 13 of 14

==> picture [596 x 99] intentionally omitted <==

Sr.
No.
Particulars Description
potential conflict of interest arising out of
such agreements, etc.
In addition, there will be no nominees
appointed to the board of directors of the
Company under the TSA.
11. In case of termination or amendment of
agreement, listed entity shall disclose
additional details to the stock exchange(s):
i. name of parties to the agreement;
ii. nature of the agreement;
iii. date of execution of the agreement;
iv. details of amendment and impact
thereof or reasons of termination and
impact thereof.

Not applicable.

Note : Capitalised terms used and not defined herein, if any, shall have the meanings ascribed to them in the main intimation.

==> picture [596 x 77] intentionally omitted <==

Page 14 of 14